GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (NAS:MIRM) » Definitions » Enterprise Value

Mirum Pharmaceuticals (Mirum Pharmaceuticals) Enterprise Value : $1,203.1 Mil (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mirum Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mirum Pharmaceuticals's Enterprise Value is $1,203.1 Mil. Mirum Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-147.3 Mil. Therefore, Mirum Pharmaceuticals's EV-to-EBIT ratio for today is -8.17.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Mirum Pharmaceuticals's Enterprise Value is $1,203.1 Mil. Mirum Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-136.5 Mil. Therefore, Mirum Pharmaceuticals's EV-to-EBITDA ratio for today is -8.81.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Mirum Pharmaceuticals's Enterprise Value is $1,203.1 Mil. Mirum Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $186.4 Mil. Therefore, Mirum Pharmaceuticals's EV-to-Revenue ratio for today is 6.46.


Mirum Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Mirum Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Enterprise Value Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 441.15 291.34 333.87 571.12 1,401.08

Mirum Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 571.12 782.95 966.68 1,474.37 1,401.08

Competitive Comparison of Mirum Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, Mirum Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirum Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Enterprise Value falls into.



Mirum Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Mirum Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Mirum Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mirum Pharmaceuticals  (NAS:MIRM) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Mirum Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1203.074/-147.319
=-8.17

Mirum Pharmaceuticals's current Enterprise Value is $1,203.1 Mil.
Mirum Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-147.3 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Mirum Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1203.074/-136.49
=-8.81

Mirum Pharmaceuticals's current Enterprise Value is $1,203.1 Mil.
Mirum Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-136.5 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Mirum Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1203.074/186.374
=6.46

Mirum Pharmaceuticals's current Enterprise Value is $1,203.1 Mil.
Mirum Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $186.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mirum Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirum Pharmaceuticals (Mirum Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Executives
Peter Radovich officer: Chief Operating Officer C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Jolanda Howe officer: SVP, Global Controller C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Lara Longpre officer: Chief Development Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Pamela Vig officer: Chief Scientific Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Christopher Peetz director, officer: President and CEO C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Patrick J Heron director, 10 percent owner 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Michael G Grey director, officer: Executive Chairman C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Eric Bjerkholt officer: Chief Financial Officer 132 PURDURE AVENUE, KENGSINGTON CA 94708
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Lon Cardon director C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Ian Clements officer: SVP Finance & Communications C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Edwin Jonathan Tucker officer: Chief Medical Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404